文献速递甲状腺疾病

糖皮质激素与替妥木单抗治疗甲状腺眼病:是否减少额外治疗需求

Corticosteroids Versus Teprotumumab for the Treatment of Thyroid Eye Disease. Does Either Mitigate the Need for Additional Treatments?
PubMed 文献 · Thyroid · 2025-12-17

本回顾性队列研究利用TriNetX平台比较静脉甲泼尼龙(IVMP)与替妥木单抗治疗甲状腺眼病后额外干预需求。倾向评分匹配后各263例,两组额外干预总发生率无显著差异,但IVMP组治疗负担更重、路径更复杂,替妥木单抗组额外药物治疗较少但更多需手术作为二线。

要点

  • 匹配后两组额外TED干预总发生率无显著差异。
  • IVMP组额外手术干预比例在12和18个月均低于替妥木单抗组。
  • 需额外干预者中IVMP组人均治疗次数更多、路径更复杂。

核心结论

  • IVMP与替妥木单抗治疗TED后额外干预总发生率相似,但IVMP治疗复杂性更高。

研究设计与样本

  • 回顾性队列研究,利用TriNetX Analytics平台识别接受IVMP或替妥木单抗的TED患者。
  • IVMP组308例,替妥木单抗组417例;倾向评分匹配后各263例,随访6、12、18个月(经6个月洗脱期)。

主要发现

  • 两组额外TED相关干预发生率无显著差异。
  • 需额外药物治疗比例:IVMP组41% vs 替妥木单抗组37%(p=0.423)。
  • 额外手术干预:12个月时IVMP组3.8% vs 替妥木单抗组8.8%(p=0.019);18个月时4.8% vs 10.0%(p=0.040)。
  • 需额外干预者中,IVMP组人均额外治疗次数2.34 vs 1.34;需≥3次额外治疗比例32.8% vs 5.5%。

临床怎么用

  • 替妥木单抗可能简化TED治疗路径,但需注意其额外手术干预比例较高。
  • IVMP治疗者若需额外干预,可能面临更复杂的治疗负担。

局限性

  • 回顾性队列设计可能存在未测量混杂。
  • 数据来源于TriNetX平台,可能存在编码或选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment paradigm for thyroid eye disease (TED) in the United States has shifted from corticosteroids toward targeted therapies such as teprotumumab. However, it remains unknown whether teprotumumab decreases the need for subsequent treatments for TED compared with intravenous methylprednisolone (IVMP). This study compares the long-term need for additional medical or surgical interventions in TED patients treated with teprotumumab versus IVMP. METHODS: A retrospective cohort study identified TED patients treated with IVMP or teprotumumab utilizing the TriNetX Analytics platform. Patients with comorbidities requiring high-dose steroids, prior TED therapy within 6 months, or concurrent TED treatments were excluded. Propensity score matching (PSM) adjusted for baseline demographic and TED-related risk factor differences. Patients were followed for 6, 12, and 18 months after a 6-month washout period. The primary outcome was the incidence of additional TED-related interventions. Secondary outcomes included post-treatment care trajectories, treatment burden, and complexity, assessed through longitudinal pathway analysis. RESULTS: The IVMP cohort included 308 patients, and the teprotumumab cohort included 417; after PSM, each contained 263 patients. No significant differences were found in the incidence of additional TED-related interventions between cohorts. A similar percentage required additional medical therapies (41% vs. 37%, p = 0.423), while fewer in the IVMP cohort underwent additional surgical interventions (3.8% vs. 8.8%, p = 0.019, 4.8% vs. 10.0%, p = 0.040) at 12 and 18 months. Among those needing additional TED interventions, the IVMP cohort exhibited a higher treatment burden and more complex treatment trajectories, requiring a greater average number of treatments (2.34 vs. 1.34 per patient; 32.8% vs. 5.5% requiring ≥3 additional treatments). CONCLUSIONS: TED patients treated with IVMP or teprotumumab had similar overall rates of additional interventions. However, IVMP was associated with greater treatment complexity, requiring more varied medical therapies. Teprotumumab-treated patients typically required fewer additional medical therapies and underwent more surgical interventions as a second-line step, suggesting that teprotumumab may simplify the treatment pathway. These data have important implications for patient education and future assessment of the cost-effectiveness of TED therapies.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Choi S, Shah SV, Chandraparnik P, et al. Corticosteroids Versus Teprotumumab for the Treatment of Thyroid Eye Disease. Does Either Mitigate the Need for Additional Treatments? Thyroid. 2025. PMID: 41467905. doi:10.1177/10507256251408731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。